Welcome to the AASLD Media page. Here you’ll find the latest AASLD press releases, information about media registration to AASLD meetings and conferences, and our media policies and guidelines. For inquiries, contact the AASLD media team at media@aasld.org.

Statement on COVID-19 Vaccination for SARS-CoV-2 in Patients with Liver Disease

May 17, 2021
As global societies committed to helping patients with liver disease, we have been closely monitoring developments around the SARSCoV-2 virus and its impact on those in our care. It is for that reason that we four societies have taken the following positions around the COVID-19 vaccination.

Read the Statement

Statement on COVID-19 Vaccination in Solid Organ Transplant Recipients

May 14, 2021
Recently, multiple studies have been published examining the response to SARS-CoV-2 mRNA-based vaccines in solid organ transplant (SOT) recipients.(1-7) Overall, these have demonstrated reduced antibody responses to vaccine when compared with reports involving the general public.

Read the Statement

Statement by the AASLD Governing Board on Violence Against Asian American/ Pacific Islander Communities

March 19, 2021
We forcefully reject the racism, sexism, bigotry, and hatred inflicted on Asian American/Pacific Islanders, other minority communities, and women, and vow to continue our work in addressing the disparities that exist in our field. With the guidance of our Inclusion and Diversity Committee, we will continue to work toward building an inclusive community, including education on structural racism and explicit and implicit bias. We stand by those who have been affected by racism, sexism, and violence, and we pledge to do our part to make this country a safer place for all Americans.

Read the Statement

AASLD Remembers Roberto Groszmann, MD, FRCP

January 22, 2021
The American Association for the Study of Liver Diseases acknowledges the passing of one of its members who made major contributions to our field. Roberto Groszmann, MD, FRCP passed away in New Haven on January 16, 2021. Dr. Groszmann made foundational discoveries in the pathophysiology of cirrhosis and portal hypertension.

Read the statement.

AASLD’s Newest Open-Access Journal to Receive First Impact Factor

December 11, 2020
AASLD announced that Hepatology Communications – AASLD’s free, open-access journal – has been accepted into Clarivate’s Science Citation Index Expanded (SCIE) and Journal Citation Reports – one of the leading citation indexes for journals of science and technology. The journal will now be eligible for an Impact Factor (IF) evaluation, which measures the frequency that a journal is cited and contributes to its reputation in the scientific community. Hepatology Communications will receive its first Impact Factor evaluation in the summer of 2021.

Read the press release.

Press Releases from The Liver Meeting® 2020

UDCA Treatment Lowers Biliary Tract Cancer, Need for Liver Transplantation in PSC Patients

November 13, 2020
Data from a new study presented this week at The Liver Meeting Digital Experience® found that ursodeoxycholic acid (UDCA) treatment has significant, positive results for patients with primary sclerosing cholangitis (PSC), including reduced incidence of biliary tract cancer, reduced mortality and less need for liver transplant.

Read the press release.

Cirrhosis in North American Women on the Rise, Trend Especially Worrisome in Young Women

November 13, 2020
Data from a new study presented this week at The Liver Meeting Digital Experience® found that the burden of cirrhosis in women in North America has increased substantially in recent years, a worrying trend driven by a rise in alcohol-related liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD).

Read the press release.

New Cases of Hepatocellular Carcinoma Disproportionately Affecting Americans in Rural Areas New Study Shows

November 13, 2020
Data from a new study presented this week at The Liver Meeting Digital Experience® found that the rate of new hepatocellular carcinoma (HCC) cases has slowed since 2009, but only in urban areas. Rural non-Hispanic whites and Blacks have experienced the greatest increases over time when comparing rural and urban HCC trends by specific demographic factors.

Read the press release.

More Women Diagnosed with HCV During Pregnancy, but Many Infants Still Not Tested Despite Recommendations from Leading Health Organizations

November 13, 2020
Data from a new study presented this week at The Liver Meeting Digital Experience® found that among pregnant women with hepatitis C virus (HCV), more than 25 percent were initially diagnosed during pregnancy screenings, which supports prenatal care as an important opportunity to screen for HCV in women.

Read the press release.

High Abdominal Fat and Low Liver Fat Combo Increases Coronary Heart Disease Risk

November 13, 2020
Data from a new study presented this week at The Liver Meeting Digital Experience® found that the distribution of a person’s body fat affects coronary heart disease risk, with an increased risk of heart events among people with a combination of high visceral adipose tissue (VAT) – abdominal fat ─ and low liver fat.

Read the press release.

Unique Coagulation Driven by IL-6 Trans-Signaling Associated with Liver Injury in COVID-19

November 13, 2020
Data from a new study presented this week at The Liver Meeting Digital Experience® found that COVID-19 coagulation impairment, driven in part by endothelial Factor VIII, is associated with liver injury in infected patients.

Read the press release.

New Machine Learning-Based Model More Accurately Predicts Liver Transplant Waitlist Mortality

November 13, 2020
Data from a new study presented this week at The Liver Meeting Digital Experience® found that using neural networks, a type of machine learning algorithm, is a more accurate model for predicting waitlist mortality in liver transplantation, outperforming the older model for end-stage liver disease (MELD) scoring.

Read the press release.

Alarming New Study Highlights Need for Improved Access to HBV Vaccination, Testing and Treatment

November 13, 2020
Data from a new study presented this week at The Liver Meeting Digital Experience® found that in 2019, more than 500,000 persons died of hepatitis B virus infection, highlighting the urgent need for universal HBV vaccination of children beginning at birth, and scaling up testing and access to care and treatment before people with the virus develop life-threatening liver cirrhosis or liver cancer.

Read the press release.

Improved Center-Specific Practices May Ease Effects of Socioeconomic Deprivation for Pediatric Liver Transplant Recipients

November 13, 2020
Data from a new study presented this week at The Liver Meeting Digital Experience® found that while neighborhood socioeconomic deprivation is associated with worse adverse long-term outcomes after liver transplant in children, improving center-specific practices can mitigate these effects for young at-risk patients.

Read the press release.

Affordable Care Act’s Medicaid Expansion Improves Liver Transplant Waitlist Placement, Especially for Certain Minorities

November 13, 2020
Data from a new study presented this week at The Liver Meeting Digital Experience® found that U.S. states that took part in the Affordable Care Act’s Medicaid expansion, which extended health care coverage to more low-income citizens, improved liver transplant waitlist placement, especially for certain racial groups.

Read the press release.

Other Press Releases / Statements

AASLD President's Statement on 2020 Nobel Prize in Medicine

October 6, 2020
The AASLD congratulates Drs. Harvey J. Alter, Michael Houghton, and Charles M. Rice, the 2020 recipients of the Nobel Prize in Physiology or Medicine. Their groundbreaking research identified the Hepatitis C virus (HCV) – a bloodborne pathogen that causes acute and chronic hepatitis, cirrhosis, and liver cancer.

Read the AASLD President's statement.

AASLD Foundation Announces Funding of over $2.2 Million in Research and Career Development Awards, Abstract Awards, and Emerging Liver Scholars Program

July 28, 2020
The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest private supporter of liver disease research and training in the United States, today announced its combined investment of over $2.2 million in Research and Career Development Awards, Abstract Awards, and its Emerging Liver Scholars (ELS) Program.

Read the press release.

JOINT GI SOCIETY MESSAGE: Visa Restrictions

July 10, 2020
To ensure that the US remains a global leader in biomedical research, the four GI Societies urge the administration to clarify their visa restrictions policy immediately to prevent the loss of talented medical and scientific professionals.

Read the joint AASLD / AGA / ACG / ASGE statement.

JOINT GI SOCIETY MESSAGE: Racism, Social Injustice and Our Pledge to Lead Change

June 2, 2020
The four GI Societies stand united in condemning racism, bigotry and discrimination based on race, religion, gender, country of origin and sexual orientation.

Read the joint AASLD / AGA / ACG / ASGE statement.

AASLD Releases Clinical Insight Guide for Treating Patients with Liver Disease and COVID-19

March 25, 2020
The American Association for the Study of Liver Diseases (AASLD) has released a clinical insight document for clinicians and frontline health care providers who are treating patients with liver disease during the COVID-19 pandemic.

Read the press release.

AASLD's "COVID-19 and the Liver" resources

March 16, 2020
AASLD is actively monitoring events related to the COVID-19 pandemic and will provide timely information and resources to support health care providers in hepatology, liver transplantation and gastroenterology as well as their patients and caregivers.

View AASLD's COVID-19 and the Liver resources.

JOINT GI SOCIETY MESSAGE: COVID-19 Clinical Insights for Our Community of Gastroenterologists and Gastroenterology Care Providers

March 15, 2020
The four GI Societies are providing important information and recommendations to consider in institutions and practices that provide endoscopy and outpatient GI services.

Read the joint AASLD / AGA / ACG / ASGE statement.

HCV Guidance Updates Recommendations for Identification and Management of Chronic Hep C

December 3, 2019
HCVguidelines.org — a website developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America to provide up-to-date guidance on the management of hepatitis C — was recently revised to reflect important developments in the identification and management of chronic hepatitis C (HCV).

Read the press release.

Matthew R. D’Uva to Join AASLD as CEO

November 20, 2019
The American Association for the Study of Liver Diseases (AASLD) has appointed Matthew R. D’Uva, FASAE, CAE, as its new chief executive officer, effective January 21, 2020.

Read the press release.

Archive of Press Releases

To view press releases from previous years, view the press release archive.